Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
12actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-03-09 | actual | When the study began enrolling |
| Primary completion | 2026-03-09 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-09 | actual | The whole study's end, after follow-up |
| First posted | 2023-02-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Sickle Cell Disease
Intervention
- Drug: Etavopivat — also filed as FT-4202
Primary outcomes
what the primary-completion date above is the date OFEffect of etavopivat on cerebral blood flow (CBF)
measured 24 weeks
Effect of etavopivat on oxygen ejection fraction (OEF)
measured 24 weeks
Effect of etavopivat on cerebral metabolic rate of oxygen (CMRO2)
measured 24 weeks
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed